Edition:
United Kingdom

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

17,576.00ZAc
9:37am BST
Change (% chg)

253.00 (+1.46%)
Prev Close
17,323.00
Open
17,400.00
Day's High
18,200.00
Day's Low
17,324.00
Volume
794,498
Avg. Vol
1,432,442
52-wk High
32,750.00
52-wk Low
16,866.00

Latest Key Developments (Source: Significant Developments)

Aspen Pharmacare Sells Global Nutritionals Business For EUR 739.8 Mln
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Aspen Pharmacare Holdings Ltd ::DIVESTMENT OF GLOBAL NUTRITIONALS BUSINESS TO LACTALIS FOR EUR739,8 MILLION.CONCLUDED AN AGREEMENT TO DIVEST OF ITS NUTRITIONALS BUSINESS TO LACTALIS GROUP.FY ASPEN IMPROVED REVENUE BY 3% TO R42,6 BILLION.FY NORMALISED HEADLINE EARNINGS PER SHARE BY 10% TO 1 605 CENTS.DEAL PROCEEDS OF EUR739,8 MILLION TO BE REDUCED BY EUR62 MILLION, WILL BE UTILISED TO BUY-OUT ASPEN'S JV PARTNERS IN NEW ZEALAND, CHINA.ANTICIPATED THAT DEAL WILL BE COMPLETED WITHIN SIX MONTHS OF SEPT. 13 ANNOUNCEMENT.STRONG OPERATING CASH FLOWS ARE ANTICIPATED TO CONTINUE.HAS DECLARED A GROSS DIVIDEND, WHICH IS PAID FROM INCOME RESERVES, OF 315 CENTS PER ORDINARY SHARE TO SHAREHOLDERS.  Full Article

Aspen Pharmacare Says Harding Loevner Holds 5.01 Pct in Co
Thursday, 12 Jul 2018 

July 12 (Reuters) - Aspen Pharmacare Holdings Ltd ::HARDING LOEVNER LP NOTIFIED CO THAT THEY ACQUIRED INTEREST IN CO'S SECURITIES, NOW AMOUNTING TO 5.01 PCT OF COMPANY, EFFECTIVE 5 JULY.  Full Article

Aspen's Infant Formula Unit Is Said To Draw Reckitt, Perrigo - Bloomberg
Wednesday, 16 May 2018 

May 16 (Reuters) - :ASPEN'S INFANT FORMULA UNIT IS SAID TO DRAW RECKITT, PERRIGO - BLOOMBERG, CITING SOURCES.FRENCH DAIRY GROUP LACTALIS AND AUSTRALIA'S INOVA PHARMACEUTICALS ARE ALSO WEIGHING OFFERS FOR A STAKE IN ASPEN'S INFANT FORMULA UNIT - BLOOMBERG.  Full Article

Aspen Says To Review Global Nutritionals Business
Monday, 29 Jan 2018 

Jan 29 (Reuters) - Aspen Pharmacare Holdings Ltd ::STRATEGIC REVIEW OF ASPEN’S GLOBAL NUTRITIONALS BUSINESS.‍HAS BEEN EXPLORING OPTIONS TO ENHANCE VALUE OF ITS GLOBAL NUTRITIONALS BUSINESS ("NUTRITIONALS") SINCE RECEIVING AN UNSOLICITED APPROACH IN Q3 OF LAST YEAR​.‍CFDA OF REGISTRATION OF ASPEN'S INFANT MILK FORMULA BRAND, ALULA, ASPEN HAS DECIDED TO FORMALISE ITS REVIEW OF STRATEGIC OPTIONS FOR NUTRITIONALS​.‍RANGE OF OPTIONS WILL BE CONSIDERED INCLUDING, INTER ALIA, INTRODUCTION OF A STRATEGIC PARTNER THAT COULD UNLOCK APPROPRIATE VALUE​.‍APPOINTED CENTERVIEW PARTNERS UK LLP AS FINANCIAL ADVISOR TO ASSIST IN STRATEGIC REVIEW PROCESS​.  Full Article

Aspen Pharmacare Receives Approval For Registration Of Alula In China​
Monday, 15 Jan 2018 

Jan 15 (Reuters) - Aspen Pharmacare Holdings Ltd ::‍ASPEN RECEIVES APPROVAL FOR REGISTRATION OF ALULA IN CHINA​.  Full Article

Aspen Pharmacare Says Has Had No Contact With Viceroy Research
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Aspen Pharmacare Holdings Ltd ::HAS HAD NO CONTACT WITH VICEROY RESEARCH AND, AS SUCH, IS UNABLE TO CONFIRM THAT SPECULATION IS CORRECT.IS NOT AWARE OF ANY INFORMATION OF A PRICE SENSITIVE NATURE THAT REQUIRES COMMUNICATION TO SHAREHOLDERS​.  Full Article

Mylan And Aspen Announce Launch Of Generic Busulfex Injection
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Mylan Nv ::MYLAN AND ASPEN ANNOUNCE LAUNCH OF GENERIC BUSULFEX® INJECTION.MYLAN NV - ‍ANNOUNCED U.S. LAUNCH OF MYLERAN INJECTION, 60 MG/10 ML SINGLE-DOSE VIAL, A GENERIC VERSION OF OTSUKA PHARMACEUTICAL'S BUSULFEX INJECTION​.  Full Article

Aspen Pharmacare says ‍UK CMA opens investigation against company
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Aspen Pharmacare Holdings Ltd :‍UK COMPETITION AND MARKETS AUTHORITY HAS OPENED AN INVESTIGATION AGAINST ASPEN​.‍INVESTIGATION INTO ANTI-COMPETITIVE CONDUCT ON SUPPLY OF FLUDROCORTISONE ACETATE 0.1 MG TABLETS, DEXAMETHASONE 2 MG TABLETS IN UK​.‍INVESTIGATION IS AT AN EARLY, INFORMATION-GATHERING STAGE.CMA CONFIRMED THAT, AT THIS TIME, IT HAS NOT REACHED ANY CONCLUSION ON WHETHER COMPETITION LAW HAS BEEN INFRINGED​.‍ASPEN IS NOT CURRENTLY IN A POSITION TO COMMENT ON INVESTIGATION​.  Full Article